Pancreatic Cancer Treatment in Shanghai: A Guide for International Patients
Pancreatic cancer is one of the most formidable diagnoses in oncology. It is the seventh leading cause of cancer death globally, with a five-year survival rate of approximately 12% across all stages — a figure that reflects both the biology of the disease and the fact that most patients are diagnosed at an advanced stage. Yet outcomes vary significantly based on where and how patients are treated. Access to high-volume surgical centers, multidisciplinary expertise, and the latest systemic therapies can meaningfully change the trajectory for individual patients.
Shanghai's leading hepatobiliary and pancreatic surgery programs are among the most experienced in Asia. For international patients seeking a second opinion, surgical evaluation, or access to clinical trials, Shanghai offers a compelling combination of surgical volume, oncological expertise, and emerging research in pancreatic cancer biology. This guide explains what to expect, which institutions and specialists to consider, and how China Medical Concierge Shanghai (CMCS) can coordinate your care.
Understanding Pancreatic Cancer: Key Facts
Histological Types: The vast majority (approximately 90%) of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC) — the aggressive exocrine tumor that most people mean when they say "pancreatic cancer." Other types include pancreatic neuroendocrine tumors (PNETs), acinar cell carcinoma, and cystic neoplasms (IPMN, MCN) with malignant potential. Treatment approaches differ significantly by histological type.
Why Early Diagnosis Is Rare: The pancreas is a retroperitoneal organ with no early warning symptoms. Most patients present with jaundice (if the tumor is in the head of the pancreas and obstructs the bile duct), abdominal or back pain, weight loss, or new-onset diabetes. By the time symptoms appear, the tumor is often locally advanced or metastatic.
Staging and Resectability: The most critical initial determination for pancreatic cancer is whether the tumor is resectable, borderline resectable, locally advanced (unresectable), or metastatic. This assessment requires high-quality cross-sectional imaging reviewed by an experienced hepatobiliary radiologist and surgeon. Staging at a high-volume center often leads to different resectability assessments than at lower-volume institutions.
Key Molecular Markers in Pancreatic Cancer
BRCA1/2 Mutations: Germline BRCA1/2 mutations are present in approximately 5–8% of pancreatic cancer patients and are associated with sensitivity to platinum-based chemotherapy and PARP inhibitors. Olaparib (Lynparza) is approved as maintenance therapy for germline BRCA-mutated metastatic pancreatic cancer that has not progressed on first-line platinum-based chemotherapy. All pancreatic cancer patients should undergo germline genetic testing.
MSI-H / dMMR: Approximately 1–2% of pancreatic cancers are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). These tumors respond to pembrolizumab (Keytruda) immunotherapy, which is approved regardless of tumor type for MSI-H/dMMR cancers. MSI testing should be performed on all pancreatic cancer patients.
KRAS Mutations: KRAS mutations are present in over 90% of PDAC and have historically been considered undruggable. However, KRAS G12C inhibitors (sotorasib, adagrasib) are now approved for KRAS G12C-mutated cancers, and KRAS G12D inhibitors are in active clinical development. KRAS G12C is present in approximately 1–2% of pancreatic cancers. Comprehensive molecular profiling (NGS panel) is recommended for all patients.
NTRK Fusions, RET Fusions, NRG1 Fusions: Rare but actionable alterations found in a small subset of pancreatic cancers. Comprehensive molecular profiling identifies these targets, which have approved or investigational therapies.
CA 19-9: The primary tumor marker for pancreatic cancer, used to monitor treatment response and detect recurrence. Note that CA 19-9 may be falsely low in patients who are Lewis antigen-negative (approximately 5–10% of the population) and falsely elevated in biliary obstruction.
Treatment by Disease Stage
Resectable Pancreatic Cancer
Surgery is the only potentially curative treatment for pancreatic cancer, and only approximately 15–20% of patients present with resectable disease. The specific operation depends on tumor location:
Pancreaticoduodenectomy (Whipple procedure): For tumors in the head of the pancreas — the most common location. This is one of the most complex abdominal operations in surgery, involving removal of the pancreatic head, duodenum, gallbladder, and part of the bile duct, followed by reconstruction. Outcomes are strongly correlated with surgical volume: high-volume centers (>20 Whipple procedures per year) have significantly lower mortality and complication rates than low-volume centers. Shanghai's leading hepatobiliary programs perform this operation with high frequency and expertise.
Distal pancreatectomy: For tumors in the body or tail of the pancreas, often performed laparoscopically at experienced centers.
Total pancreatectomy: For tumors involving the entire pancreas or multifocal disease.
Perioperative chemotherapy: Current evidence supports perioperative chemotherapy (before and/or after surgery) rather than surgery alone. Modified FOLFIRINOX (mFOLFIRINOX) or gemcitabine + nab-paclitaxel are the standard regimens. Neoadjuvant chemotherapy before surgery may improve R0 resection rates and select patients who are likely to benefit from surgery.
Borderline Resectable Pancreatic Cancer
Borderline resectable tumors involve major vascular structures (portal vein, superior mesenteric artery/vein) but may become resectable after neoadjuvant chemotherapy and/or radiation. This is an area where expert multidisciplinary assessment is critical — what is deemed unresectable at one center may be resectable at a high-volume center with vascular surgery expertise. CMCS facilitates second-opinion surgical evaluations specifically for patients in this category.
Locally Advanced (Unresectable) Pancreatic Cancer
For tumors that encircle major vessels and cannot be safely resected, the goal shifts to systemic disease control and local tumor management. Options include:
- Systemic chemotherapy (FOLFIRINOX or gemcitabine + nab-paclitaxel) with reassessment for conversion to resectability
- Stereotactic body radiotherapy (SBRT) for local control
- Irreversible electroporation (IRE / NanoKnife) — a non-thermal ablation technique available at select Shanghai centers for locally advanced tumors near critical vessels
- Clinical trial participation
Metastatic Pancreatic Cancer
For patients with metastatic disease, systemic chemotherapy remains the backbone of treatment:
FOLFIRINOX / modified FOLFIRINOX: A combination of oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil. More active than gemcitabine-based regimens in fit patients, with median overall survival of approximately 11 months in the metastatic setting. Requires good performance status.
Gemcitabine + nab-paclitaxel (Abraxane): An effective and better-tolerated alternative for patients who cannot receive FOLFIRINOX. Median overall survival approximately 8–9 months.
PARP inhibitors (BRCA-mutated): Olaparib maintenance therapy for germline BRCA-mutated patients who have not progressed on first-line platinum-based chemotherapy.
Pembrolizumab (MSI-H/dMMR): For the rare MSI-H pancreatic cancer patient, immunotherapy can produce durable responses.
Second-line chemotherapy: Nanoliposomal irinotecan (nal-IRI) + 5-FU/leucovorin (NAPOLI-1 regimen) is approved for gemcitabine-refractory metastatic pancreatic cancer. Oxaliplatin-based regimens are used after FOLFIRINOX failure.
Clinical trials: Pancreatic cancer is an area of intense research. Trials in Shanghai include novel KRAS inhibitors, cancer vaccines, CAR-T approaches, and combination immunotherapy strategies. Molecular profiling to identify actionable targets is essential before enrolling in trials.
Biliary Obstruction: Managing Jaundice
Many pancreatic head tumors cause biliary obstruction, leading to jaundice, itching, and impaired liver function. Biliary drainage — via endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, or percutaneous transhepatic biliary drainage (PTBD) — is often required before systemic treatment can begin. Shanghai's leading centers have expert interventional endoscopy and interventional radiology teams for this purpose.
Leading Shanghai Specialists for Pancreatic Cancer
Fudan University Shanghai Cancer Center (FUSCC)
FUSCC's Department of Pancreatic Surgery is one of China's most specialized and highest-volume pancreatic cancer programs. CMCS works with Prof. Yu Xianjun (虞先峻), Director of Pancreatic Surgery at FUSCC, who is nationally recognized for his expertise in pancreatic cancer surgery and research. Prof. Yu's team has published extensively on pancreatic cancer outcomes and has been involved in landmark clinical trials in this disease.
Zhongshan Hospital — Fudan University
Zhongshan Hospital's hepatobiliary surgery department is one of China's most experienced for complex pancreatic resections, including Whipple procedures with vascular reconstruction. Its integrated hepatobiliary, interventional radiology, and oncology teams provide comprehensive multidisciplinary care.
Ruijin Hospital — Shanghai Jiao Tong University
Ruijin Hospital has an active pancreatic surgery and oncology program, with particular strength in minimally invasive pancreatic surgery and multidisciplinary tumor board management.
Eastern Hepatobiliary Surgery Hospital
As a dedicated hepatobiliary specialty hospital, Eastern Hepatobiliary Surgery Hospital has extensive experience with complex pancreatic cases, including borderline resectable tumors requiring vascular involvement management.
The Importance of a Second Opinion
Pancreatic cancer is a disease where a second surgical opinion can be life-changing. Studies consistently show that resectability assessments vary significantly between centers, and that patients deemed unresectable at community hospitals are sometimes found to be resectable at high-volume specialty centers. For international patients who have been told their tumor is unresectable, a second opinion at a Shanghai hepatobiliary center is strongly recommended before accepting that conclusion.
CMCS facilitates rapid second-opinion consultations, including remote imaging review by Shanghai's leading hepatobiliary surgeons before any travel commitment is made.
What to Prepare Before Your Shanghai Consultation
- CT of the abdomen and pelvis with pancreatic protocol (thin-slice, triphasic contrast) — digital DICOM files essential for surgical resectability assessment
- MRI abdomen with MRCP if available
- PET-CT for staging if available
- Pathology report with histological diagnosis and any molecular testing results
- Comprehensive molecular profiling (NGS panel) if available — including KRAS, BRCA1/2, MSI status, TMB
- Germline genetic testing results (BRCA1/2 and broader hereditary cancer panel)
- CA 19-9 and CEA tumor marker levels (most recent)
- Liver function tests and bilirubin (to assess biliary obstruction)
- Prior treatment records: chemotherapy regimens, cycles, response assessments
- Endoscopy/ERCP reports if biliary stenting has been performed
How CMCS Coordinates Pancreatic Cancer Care in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For pancreatic cancer patients, our coordination includes:
- Rapid case triage and imaging review to assess resectability before travel
- Medical record translation and clinical summary preparation
- Multidisciplinary tumor board submission and review coordination
- Appointment scheduling across pancreatic surgery, medical oncology, interventional endoscopy, and radiation oncology
- On-site interpretation during all consultations and procedures
- Clinical trial eligibility assessment and molecular profiling coordination
- Biliary drainage coordination if required before systemic treatment
- Post-treatment follow-up and surveillance coordination
- Liaison with the patient's home oncologist for continuity of care
Contact CMCS to Begin Your Consultation
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.
0 commenti